Victor H Borja-Aburto
Overview
Explore the profile of Victor H Borja-Aburto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wacher N, Gomez-Diaz R, Valdez-Gonzalez A, Duque-Lopez X, Moran-Villota S, Mondragon-Gonzalez R, et al.
Rev Med Inst Mex Seguro Soc
. 2024 Nov;
62(suppl 2):1-12.
PMID: 39602549
Background: It has been proposed the current nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD) as a general term to encompass the various etiologies of steatosis and to include the...
2.
Gutierrez J, Olaiz G, Juarez-Flores A, Borja-Aburto V, Ascencio-Montiel I, Bertozzi S
PLoS One
. 2023 Dec;
18(12):e0296320.
PMID: 38128048
Background: The COVID-19 pandemic has progressed rapidly, with the emergence of new virus variants that pose challenges in treating infected individuals. In Mexico, four epidemic waves have been recorded with...
3.
Olaiz G, Bertozzi S, Juarez-Flores A, Borja-Aburto V, Vicuna F, Ascencio-Montiel I, et al.
Front Public Health
. 2023 Mar;
11:1102498.
PMID: 36923037
Background: Timely monitoring of SARS-CoV-2 variants is crucial to effectively managing both prevention and treatment efforts. In this paper, we aim to describe demographic and clinical patterns of individuals with...
4.
Double or triple combination therapy in systemic arterial hypertension: to whom, when and with what?
Rosas-Peralta M, Borrayo-Sanchez G, Alcocer L, Duran-Arenas J, Borja-Aburto V
Gac Med Mex
. 2020 Jun;
156(3):224-227.
PMID: 32539018
No abstract available.
5.
Avelino-Silva V, Mayaud P, Tami A, Miranda M, Rosenberger K, Alexander N, et al.
BMC Infect Dis
. 2019 Dec;
19(1):1081.
PMID: 31878895
Background: The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites were selected over...
6.
Wacher N, Gomez-Diaz R, Ascencio-Montiel I, Rascon-Pacheco R, Aguilar-Salinas C, Borja-Aburto V
Diabetes Res Clin Pract
. 2019 Dec;
159:107949.
PMID: 31794808
Aims: To describe the annual incidence of type 1 diabetes in children and adolescents insured by the Mexican Institute of Social Security, the main health provider in Mexico, during 2000-2018....
7.
Bustamante-Montes L, Flores-Meza B, Hernandez-Valero M, Cardenas-Lopez A, Dolores-Velazquez R, Borja-Bustamante P, et al.
Arch Med Res
. 2019 Nov;
50(6):393-399.
PMID: 31689664
Background: Night shift work involving circadian disruption has been associated with increased breast cancer rates in some epidemiological studies, but the evidence is still on debate. Aim Of The Study:...
8.
Venkatesan S, Myles P, Bolton K, Muthuri S, Al Khuwaitir T, Anovadiya A, et al.
J Infect Dis
. 2019 Jul;
221(3):356-366.
PMID: 31314899
Background: The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear. Methods: We conducted a one-stage individual participant data (IPD) meta-analysis...
9.
Ovalle-Luna O, Jimenez-Martinez I, Rascon-Pacheco R, Gomez-Diaz R, Valdez-Gonzalez A, Gamiochipi-Cano M, et al.
Gac Med Mex
. 2019 Feb;
155(1):30-38.
PMID: 30799453
Introduction: The prevalence of chronic complications and comorbidities in patients with type 2 diabetes (T2D) has increased worldwide. Objective: To compare the prevalence of complications and chronic comorbidities in patients...
10.
Wacher N, Reyes-Sanchez M, Vargas-Sanchez H, Gamiochipi-Cano M, Rascon-Pacheco R, Gomez-Diaz R, et al.
Prim Care Diabetes
. 2017 Mar;
11(3):297-304.
PMID: 28343902
Aims: Describe stepwise strategies (electronic chart review, patient preselection, call-center, personnel dedicated to recruitment) for the successful recruitment of >5000 type 2 diabetes patients in four months. Methods: Twenty-five family...